PharmaTher Holdings Ltd (TSE:PHRM) has released an update.
PharmaTher Holdings Ltd.’s affiliate, Sairiyo Therapeutics, has been greenlit to start a Phase 1 clinical trial in Australia for PD-001, a reformulated version of the drug cepharanthine, which shows promise in treating cancers and medical emergencies. The success of the trial could lead to advanced clinical trials in the U.S. and further leverage cepharanthine’s historically recognized therapeutic benefits, despite its low oral bioavailability in the past.
For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.
